Darexaban
≥99%
- Product Code: 109967
CAS:
365462-23-3
| Molecular Weight: | 474.55 g./mol | Molecular Formula: | C₂₇H₃₀N₄O₄ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | 2-8°C, sealed, dry |
Product Description:
Darexaban is primarily investigated for its anticoagulant properties, making it a candidate for preventing and treating conditions related to blood clots. It is studied for use in patients with atrial fibrillation to reduce the risk of stroke and systemic embolism. Additionally, it has been explored for its potential in managing venous thromboembolism, including deep vein thrombosis and pulmonary embolism. Its mechanism involves inhibiting factor Xa, a key component in the blood coagulation cascade, which helps in preventing the formation of clots. Clinical trials have assessed its efficacy and safety compared to existing anticoagulants, aiming to offer an alternative with potentially fewer side effects or better patient outcomes. However, its development status and approval may vary across regions, and it is essential to consult current medical guidelines for its use.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | $464.94 |
+
-
|
| 0.010 | 10-20 days | $760.82 |
+
-
|
| 0.025 | 10-20 days | $1,521.63 |
+
-
|
Darexaban
Darexaban is primarily investigated for its anticoagulant properties, making it a candidate for preventing and treating conditions related to blood clots. It is studied for use in patients with atrial fibrillation to reduce the risk of stroke and systemic embolism. Additionally, it has been explored for its potential in managing venous thromboembolism, including deep vein thrombosis and pulmonary embolism. Its mechanism involves inhibiting factor Xa, a key component in the blood coagulation cascade, which helps in preventing the formation of clots. Clinical trials have assessed its efficacy and safety compared to existing anticoagulants, aiming to offer an alternative with potentially fewer side effects or better patient outcomes. However, its development status and approval may vary across regions, and it is essential to consult current medical guidelines for its use.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
$0.00
$0.00
Total :